FTAL:TASEFattal Holdings (1998) Ltd. Analysis
Data as of 2026-07-08 - not real-time
ILA 74,290.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Fattal Holdings is trading just below its short‑term moving average, with the price hugging the 20‑day SMA and comfortably above the 200‑day SMA, suggesting a modest technical support level. The RSI sits in the upper‑mid range, indicating momentum but not yet overbought, while the MACD histogram is positive, delivering a bullish signal despite the MACD line remaining in negative territory. Overall market direction is neutral, and volume has been stable, yet the stock has exhibited elevated recent volatility, reflecting the sensitivity of the lodging sector to travel demand fluctuations. The company carries a very high leverage profile, with debt far outweighing equity, and it is reporting negative earnings per share and slim profit margins, leaving little room for dividend sustainability. Cash generation from operations is modest and free cash flow is negative, underscoring cash‑flow pressure. The price‑to‑book multiple is above two, and the price‑to‑sales ratio suggests the market is assigning a premium despite weak fundamentals.
Given the combination of high leverage, negative profitability, and a valuation that appears stretched, the stock leans toward being overvalued and aligns more with a value‑oriented assessment rather than a growth story. The risk landscape is tilted higher due to sector cyclicality, regional exposure, and limited liquidity, while the low beta tempers systematic market risk. Consequently, the outlook favors caution, with short‑term positioning leaning toward a hold, and medium‑ to long‑term recommendations shifting toward a sell stance.
Given the combination of high leverage, negative profitability, and a valuation that appears stretched, the stock leans toward being overvalued and aligns more with a value‑oriented assessment rather than a growth story. The risk landscape is tilted higher due to sector cyclicality, regional exposure, and limited liquidity, while the low beta tempers systematic market risk. Consequently, the outlook favors caution, with short‑term positioning leaning toward a hold, and medium‑ to long‑term recommendations shifting toward a sell stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near short‑term moving average
- positive MACD histogram
- stable volume
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- high debt‑to‑equity ratio
- negative earnings and cash flow
- elevated sector cyclicality
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- overvalued pricing relative to fundamentals
- ongoing leverage concerns
- lack of dividend income
Key Metrics & Analysis
Financial Health
Revenue Growth-4.70%
Profit Margin-0.10%
ROE-0.04%
ROA2.25%
Debt/Equity531.14
P/B Ratio2.9
Op. Cash FlowILA1.0B
Free Cash FlowILA-529889504
Technical Analysis
TrendNeutral
RSI58.5
SupportILA 68,360.00
ResistanceILA 80,380.00
MA 20ILA 74,132.50
MA 50ILA 75,968.60
MA 200ILA 65,109.60
MACDBullish
VolumeStable
Fear & Greed Index92.63
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta0.58
Volatility37.30%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.